|Bid||32.47 x 1100|
|Ask||32.60 x 1100|
|Day's Range||31.72 - 34.86|
|52 Week Range||9.53 - 70.29|
|Beta (5Y Monthly)||1.41|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 08, 2021 - Nov. 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||70.88|
The U.S. Food and Drug Administration (FDA) granted approval for the company's autoimmune drug, avacopan, which instantly led to shares of ChemoCentryx more than doubling in value. For investors who didn't want to take on the risk heading into the FDA decision, the obvious question now is whether it's too late to invest in the healthcare stock. After amassing such impressive returns over a short time frame, can investors who buy the stock today still expect to earn a good return on their investment?
Growth stocks can be a thing of beauty. The trick, if you will, is to suss out growth stocks that won't rot on the vine, so to speak. While both of these biotech stocks have more than doubled in value in the past three years, I believe each of these healthcare equities still has a lot of room to run in 2022 and beyond.